Results of glioblastoma clinical trial show safety and clinical benefit of CAR T cell therapy

April 21, 2017, Baylor College of Medicine

Glioblastoma is the most common brain tumor in humans and also one of the most difficult cancers to treat; patients with this type of cancer only survive about one year from time of diagnosis. Researchers at Baylor College of Medicine, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor, Texas Children's Hospital and Houston Methodist are investigating a new treatment option using modified T cells with anti-tumor properties with the goal of improving outcomes for patients with glioblastoma.

Their research focuses on engineered T cells that target the protein HER 2 expressed in low levels in . Results of a Phase 1 study published in the current issue of JAMA Oncology established the safety of these HER 2-specific, chimeric antigen receptor modified T cells (CAR T cells) when infused in to patients in increasing doses and, importantly, results also showed a clinical benefit to patients.

"Our inability to effectively treat glioblastoma has been one of the failures of oncology," said Dr. Nabil Ahmed, associate professor of pediatrics at Baylor, Texas Children's Cancer Center and the Center for Cell and Gene Therapy and first author of the paper. "Glioblastoma is resistant to standard therapy, and it is difficult to remove all of the through surgery without damaging the brain, so there is an urgent need for new and better treatment. Our work has focused on immune therapy, because it is very targeted and uses tumor-killing mechanisms that the cancers have not shown resistance to in the lab."

CAR T cells are T cells – a type of involved in the defense against tumors – that have been programmed to recognize and kill tumor cells carrying one specific antigen, in this case HER2, on the surface of through an artificial molecule, the CAR, expressed on their surface.

The study included 17 pediatric and adult patients with HER 2-positive glioblastoma who received up to five escalating doses of the engineered T cells through intravenous infusions. Establishing the safety of the treatment is important, as other immunotherapy treatment approaches for solid tumors have resulted in significant side effects and toxicities for patients, Ahmed said.

"First and foremost, the cells were safe. We did not see any life threatening side effects. Along with this we also saw measurable tumor responses," Ahmed said.

Median survival of patients who participated in the trial was 11.1 months post T cell infusion and 24.5 months from diagnosis. Three in the trial experienced no disease progression after more than two years of follow up.

With their promising results, Ahmed and his research colleagues, including Dr. Stephen Gottschalk, professor of pediatrics at Baylor, Texas Children's Cancer Center and the Center for Cell and Gene Therapy and senior author of the paper, turn their focus to the next steps in the research.

"In this phase 1 clinical trial we tested a particular modification that renders these cells specific for HER 2 and while the results have been encouraging, we are very interested to further engineer these cells, for example by making the T cells more effective after the infusion and by targeting not only HER2 but other molecules that are expressed on the cell surface of brain tumors," Gottschalk said.

The CAR T are produced in the cell manufacturing facility of the Center for Cell and Gene Therapy. Baylor is one of the few academic institutions that has such a facility, Gottschalk noted.

Explore further: Dual antigen targeting may improve CAR T cell cancer therapy

More information: Nabil Ahmed et al. HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma, JAMA Oncology (2017). DOI: 10.1001/jamaoncol.2017.0184

Related Stories

Dual antigen targeting may improve CAR T cell cancer therapy

July 18, 2016
A solid tumor comprises a heterogeneous population of cells that differ from each other on their type of surface molecules. In an article published today in the Journal of Clinical Investigation, researchers from Baylor College ...

Special T cells that target solid tumors offer potential treatment for pediatric and adult cancers

September 14, 2016
Adoptive cell-therapies, in which a patient's own immune cells are used to recognize and target tumors, have shown breakthrough results for patients with certain B-cell malignancies, or cancers of the blood, but this therapy ...

Personalized cell therapies show more promise in solid tumors

April 10, 2017
Investigational "hunter" immune cells engineered to seek out and attack a deadly brain cancer known as glioblastoma (GBM) infiltrated patients' tumors and triggered thousands of more T cells once inside, researchers from ...

Case report: Adoptive T-cell Tx shows promise in glioblastoma

December 29, 2016
(HealthDay)—Treatment with autologous chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2) is associated with tumor regression in recurrent ...

Combination therapy for glioblastoma shows promising results in early-stage research

January 25, 2017
UCLA researchers have discovered that combining a vaccine developed at UCLA with other experimental therapies and FDA-approved treatments shows promise for reducing the size of advanced brain tumors. The immunotherapy, which ...

Immunotherapy, gene therapy combination shows promise against glioblastoma

January 4, 2017
"Devastating" and "dismal." That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.

Recommended for you

Researchers discover novel mechanism linking changes in mitochondria to cancer cell death

February 20, 2018
To stop the spread of cancer, cancer cells must die. Unfortunately, many types of cancer cells seem to use innate mechanisms that block cancer cell death, therefore allowing the cancer to metastasize. While seeking to further ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.